Oxidative Stress in Parkinson's Disease
暂无分享,去创建一个
[1] C. Marsden,et al. α‐tocopherol levels in brain are not altered in Parkinson's disease , 1992 .
[2] C. Shults. Lewy bodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[3] Min Zhu,et al. Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. , 2006, Biochemistry.
[4] Pasko Rakic,et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] E. Hirsch,et al. The Role of Glial Reaction and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[6] J. Trojanowski,et al. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. , 2005, Biochemistry.
[7] J. Trojanowski,et al. Reversible Inhibition of α-Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations* , 2005, Journal of Biological Chemistry.
[8] Michael Zuker,et al. Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..
[9] Makoto Hashimoto,et al. Transgenic Models of α‐Synuclein Pathology , 2003 .
[10] M. Beal,et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients , 1998, Neurology.
[11] M. Vila,et al. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] M. Fortini. Faculty Opinions recommendation of Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. , 2003 .
[13] Xiongwei Zhu,et al. Mitochondrial failures in Alzheimer's disease , 2004, American journal of Alzheimer's disease and other dementias.
[14] T. Dawson,et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase , 2007, Proceedings of the National Academy of Sciences.
[15] D. Ben-shachar,et al. Iron, melanin and dopamine interaction: relevance to parkinson's disease , 1993, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[16] J. Trojanowski,et al. More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases , 2004, Trends in Neurosciences.
[17] T. Rouault. Post-transcriptional regulation of human iron metabolism by iron regulatory proteins. , 2002, Blood cells, molecules & diseases.
[18] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[19] C. Moraes,et al. Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology* , 1999, The Journal of Biological Chemistry.
[20] T. Hastings. Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase , 1995, Journal of neurochemistry.
[21] B. Westerink,et al. Brain dialysis in conscious rats reveals an instantaneous massive release of striatal dopamine in response to MPP+. , 1986, European journal of pharmacology.
[22] G. Perry,et al. Metal ions and oxidative protein modification in neurological disease. , 2005, Annali dell'Istituto superiore di sanita.
[23] E. Masliah,et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Trojanowski,et al. Parkinson's Disease and Related α‐Synucleinopathies Are Brain Amyloidoses , 2003, Annals of the New York Academy of Sciences.
[25] S. Pennathur,et al. Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.
[26] Tony Wyss-Coray,et al. Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.
[27] Y. Agid,et al. Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.
[28] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[29] E. Floor,et al. Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.
[30] R. Marttila,et al. Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.
[31] R. Palmiter,et al. Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity , 2005, BMC Neuroscience.
[32] T. Niki,et al. DJ‐1 has a role in antioxidative stress to prevent cell death , 2004, EMBO reports.
[33] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[34] S. Mandel,et al. Early and Late Gene Changes in MPTP Mice Model of Parkinson's Disease Employing cDNA Microarray , 2002, Neurochemical Research.
[35] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[36] M. Youdim. Brain monoamine oxidase (MAO) B: A unique neurotoxin and neurotransmitter producing enzyme , 1989, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[37] B. Halliwell. Oxygen radicals: a commonsense look at their nature and medical importance. , 1984, Medical biology.
[38] M. Elstner,et al. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions , 2008, Journal of Neurology.
[39] M. Beal,et al. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects , 1997, Annals of neurology.
[40] J. Mills,et al. Asynchronous Death as a Characteristic Feature of Apoptosis , 1999 .
[41] S. Lindquist,et al. α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.
[42] Manisha Patel,et al. Iron‐sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease , 2004, Journal of neurochemistry.
[43] G. Perry,et al. Sequestration of iron by Lewy bodies in Parkinson’s disease , 2000, Acta Neuropathologica.
[44] L. Tremblay,et al. Experimental Models of Parkinson’s Disease , 2002, Annales pharmaceutiques francaises.
[45] T. Mak,et al. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 , 2006, Proceedings of the National Academy of Sciences.
[46] M. Youdim. Deficiency and excess of iron in brain function and dysfunction. , 2009, Nutrition reviews.
[47] D. Selkoe,et al. Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.
[48] R. Palmiter,et al. Dopamine Depletion Does Not Protect against Acute 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Toxicity In Vivo , 2005, The Journal of Neuroscience.
[49] J. Trojanowski,et al. Cleavage of α-Synuclein by Calpain: Potential Role in Degradation of Fibrillized and Nitrated Species of α-Synuclein† , 2005 .
[50] A. Fink. The Aggregation and Fibrillation of α-Synuclein , 2006 .
[51] G. Kreutzberg. Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.
[52] Li Qian,et al. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila , 2006, Proceedings of the National Academy of Sciences.
[53] A. Schapira. Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.
[54] M. Selley. (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. , 1998, Free radical biology & medicine.
[55] S. Korsmeyer,et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[56] N. Hattori,et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[57] T. Rouault,et al. Brain iron metabolism. , 2006, Seminars in pediatric neurology.
[58] Kexiang Xu,et al. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging , 2006, Proceedings of the National Academy of Sciences.
[59] P. Lansbury,et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[60] C. Marsden,et al. Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.
[61] Konstantin Khrapko,et al. Recombination of Human Mitochondrial DNA , 2004, Science.
[62] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[63] Sid Gilman,et al. Widespread Alterations of α-Synuclein in Multiple System Atrophy , 1999 .
[64] K. Jellinger,et al. Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.
[65] K. Ohno,et al. Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease. , 1991, Biochemical and biophysical research communications.
[66] K. Jellinger,et al. Mitochondrial DNA in Postmortem Brain from Patients with Parkinson's Disease , 1991, Journal of neurochemistry.
[67] J. Schulz,et al. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.
[68] E. Hirsch,et al. Animal models of Parkinson's disease in rodents induced by toxins: an update. , 2003, Journal of neural transmission. Supplementum.
[69] L. Thal,et al. Characterization of the human α-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms 1 , 2001 .
[70] B. Halliwell,et al. Oxygen toxicity, oxygen radicals, transition metals and disease. , 1984, The Biochemical journal.
[71] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[72] Takeshi Iwatsubo,et al. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia , 1998, Cell Death and Differentiation.
[73] R D Klausner,et al. A cis-acting element is necessary and sufficient for translational regulation of human ferritin expression in response to iron. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[74] R. Klausner,et al. Regulating the fate of mRNA: The control of cellular iron metabolism , 1993, Cell.
[75] Claudia M Testa,et al. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. , 2005, Brain research. Molecular brain research.
[76] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[77] K. Okamoto,et al. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease , 2004, Journal of the Neurological Sciences.
[78] Todd B. Sherer,et al. Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.
[79] M. Youdim,et al. A model of MPTP-induced Parkinson's disease in the goldfish , 2007, Nature Protocols.
[80] K. Jellinger,et al. Neuropathological spectrum of synucleinopathies , 2003, Movement disorders : official journal of the Movement Disorder Society.
[81] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[82] C. Ferrarese,et al. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: Negative correlation with levodopa dosage , 2006, Neurobiology of Disease.
[83] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[84] C D Marsden,et al. Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.
[85] S. Przedborski. Neuroinflammation and Parkinson's disease. , 2007, Handbook of clinical neurology.
[86] H. M. Swartz,et al. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain , 1996, Neuroscience.
[87] Peter T. Lansbury,et al. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.
[88] T. Montine,et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.
[89] G. Perry,et al. Biochemistry of Neurodegeneration , 2001, Science.
[90] A. Eklund,et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein , 2008, Proceedings of the National Academy of Sciences.
[91] E. Hirsch,et al. How to judge animal models of Parkinson's disease in terms of neuroprotection. , 2006, Journal of neural transmission. Supplementum.
[92] T. Joh,et al. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease , 2006, Experimental & Molecular Medicine.
[93] R. Palmiter,et al. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic , 1995, Cell.
[94] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[95] M. Beal,et al. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice , 1998, Brain Research.
[96] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[97] Kim J. Krishnan,et al. Age related mitochondrial degenerative disorders in humans , 2008, Biotechnology journal.
[98] M. Vila,et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[99] A. Nunomura,et al. Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies , 2002, Neuroreport.
[100] J. Trojanowski,et al. Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.
[101] B. Ames,et al. Assays for 8-hydroxy-2'-deoxyguanosine: a biomarker of in vivo oxidative DNA damage. , 1991, Free radical biology & medicine.
[102] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[103] M. Beal. Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[104] C. Marsden,et al. A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.
[105] Sarah J Tabrizi,et al. Models of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[106] A. Graybiel,et al. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.
[107] S. Przedborski,et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[108] K. Takeshige,et al. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. , 1990, Biochemical and biophysical research communications.
[109] S. Przedborski,et al. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice , 2006, Proceedings of the National Academy of Sciences.
[110] D. D. Di Monte,et al. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. , 2007, The Journal of biological chemistry.
[111] J. Poirier,et al. Superoxide Dismutase Expression in Parkinson's Disease , 1994, Annals of the New York Academy of Sciences.
[112] R. Ramsay,et al. Relation of superoxide generation and lipid peroxidation to the inhibition of NADH-Q oxidoreductase by rotenone, piericidin A, and MPP+. , 1992, Biochemical and biophysical research communications.
[113] G. Perry,et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[114] Todd B. Sherer,et al. Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.
[115] M. Block,et al. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.
[116] P. Mcgeer,et al. Inflammation and neurodegeneration in Parkinson's disease. , 2004, Parkinsonism & related disorders.
[117] C. Marsden,et al. Alpha-tocopherol levels in brain are not altered in Parkinson's disease. , 1992, Annals of neurology.
[118] M. V. Van Woert,et al. Brain peroxidase and catalase in Parkinson disease. , 1975, Archives of neurology.
[119] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[120] Yasuto Itoyama,et al. Systemic Increase of Oxidative Nucleic Acid Damage in Parkinson's Disease and Multiple System Atrophy , 2002, Neurobiology of Disease.
[121] A. Kupsch,et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. , 2007, Archives of neurology.
[122] M. Beal,et al. Prospects for redox-based therapy in neurodegenerative diseases , 2009, Neurotoxicity Research.
[123] D. Lynch,et al. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. , 2004, The Journal of biological chemistry.
[124] C. Marsden,et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.
[125] J. Schulz,et al. Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.
[126] K. Sakumi,et al. Oxidative damage in nucleic acids and Parkinson's disease , 2007, Journal of neuroscience research.
[127] K. O’Malley,et al. The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.
[128] R. Klausner,et al. The impact of oxidative stress on eukaryotic iron metabolism. , 1996, EXS.
[129] Takashi Uehara,et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[130] J. Trojanowski,et al. Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .
[131] M. Oechsner,et al. Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication , 2004, Neurobiology of Disease.
[132] G. Zeevalk,et al. Role for Dopamine in Malonate‐Induced Damage In Vivo in Striatum and In Vitro in Mesencephalic Cultures , 2000, Journal of neurochemistry.
[133] S. Rhee. Cell signaling. H2O2, a necessary evil for cell signaling. , 2006, Science.
[134] D. D. Di Monte,et al. Effect of 4-Hydroxy-2-nonenal Modification on α-Synuclein Aggregation* , 2007, Journal of Biological Chemistry.
[135] C. Shults,et al. Clinical trials of coenzyme Q10 in neurological disorders , 2005, BioFactors.
[136] J. Trojanowski,et al. Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.
[137] H. Tohgi,et al. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease , 2003, Neuroscience Letters.
[138] R. Tanzi,et al. The 5′-untranslated region of Parkinson's disease α-synuclein messengerRNA contains a predicted iron responsive element , 2007, Molecular Psychiatry.
[139] G. Cha,et al. Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. , 2005, Gene.
[140] M. Vila,et al. Genetic clues to the pathogenesis of Parkinson's disease , 2004, Nature Medicine.
[141] T. Montine,et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans , 2002, Neuroscience Letters.
[142] J. Langston,et al. Model fusion: The next phase in developing animal models for parkinson’s disease , 2007, Neurotoxicity Research.
[143] K. Jellinger. Lewy body-related α-synucleinopathy in the aged human brain , 2004, Journal of Neural Transmission.
[144] K. Gwinn‐Hardy. Genetics of parkinsonism , 2002, Movement disorders : official journal of the Movement Disorder Society.
[145] Mark A. Wilson,et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[146] R. Burke,et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[147] E. Hirsch,et al. The rotenone model of parkinsonism--the five years inspection. , 2006, Journal of neural transmission. Supplementum.
[148] C. Marsden,et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.
[149] P Riederer,et al. The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. , 1993, Advances in neurology.
[150] S. Kish,et al. Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.
[151] A. Lees,et al. A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.
[152] Wenbo Zhou,et al. DJ-1 Up-regulates Glutathione Synthesis during Oxidative Stress and Inhibits A53T α-Synuclein Toxicity* , 2005, Journal of Biological Chemistry.
[153] S. Rhee,et al. H2O2, a Necessary Evil for Cell Signaling , 2006, Science.
[154] D. Sulzer,et al. α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration , 2006, The Journal of Neuroscience.
[155] Virginia M. Y. Lee,et al. Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.
[156] N. Paricio,et al. Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. , 2007, Gene.
[157] David S. Park,et al. Role of Cdk5-Mediated Phosphorylation of Prx2 in MPTP Toxicity and Parkinson's Disease , 2007, Neuron.
[158] M. Smith,et al. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. , 2007, CNS & neurological disorders drug targets.
[159] Peter T. Lansbury,et al. Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.
[160] J. Troncoso,et al. S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function , 2004, Science.
[161] H. Braak,et al. Nigral and extranigral pathology in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.
[162] John Hardy,et al. The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.
[163] B. Halliwell,et al. 1 Iron toxicity and oxygen radicals , 1989 .
[164] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[165] Robert W. Taylor,et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease , 2006, Nature Genetics.
[166] S J Kish,et al. Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.
[167] Woojin Jeong,et al. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications , 2005, Trends in Molecular Medicine.
[168] M. Smith,et al. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease , 1996, Brain Research.
[169] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.